[1] |
Tabata R,Tabata C,Kita Y.Management of myocardial infarction in immune thrombocytopenic purpura with antiphospholipid antibodies[J].JThromb Thrombolysis,2013,35 (1):115-118.
|
[2] |
Elhoseiny SM,Morgan DS,Elhadidy KE.The association of lymphoid protein tyrosine phosphatase non-receptor 22 (PTPN 22)gene polymorphism with Egyptian immune thrombocytopenic purpura[J].Comparative Clin Pathol,2013,22(3):395-402.
|
[3] |
邵学谦.单孔腹腔镜脾切除术与传统腹腔镜脾切除术的对照研究[J].中国内镜杂志,2014,20(20):805-807.
|
[4] |
Talaat RM,Elmaghraby AM,Barakat SS,et al.Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura(ITP)[J].Clin Exp Immunol,2014,176(2):291-300.
|
[5] |
马利锋,康建省,李涛,等.腹腔镜脾切除术治疗115例免疫性血小板减少症的疗效分析[J].重庆医学,2014,43(10):1199-1200.
|
[6] |
Stotler BA,Schwartz J.How we use WinRho in patientswith idiopathic thrombocytopenic purpura[J].Transfusion,2016,55(11):2547-2550.
|
[7] |
艾尔肯·阿皮孜,孙培春.腹腔镜脾切除术治疗免疫性血小板减少性紫癜的回顾性研究[J].医药论坛杂志,2015,36(9):93-94.
|
[8] |
闫慧明,贾彬,张平.难治性特发性血小板减少型紫癜脾切除的临床分析[J].中国普通外科杂志,2012,21(6):700-703.
|
[9] |
王春荣.腹腔镜下脾切除术治疗46例特发性血小板减少性紫瘫的临床疗效观察[J].贵州医药,2014,38(10):891-892.[10]Rijcken E,Mees ST,Bisping G,et al.Laparoscopic splenectomy for medically refractory immune thrombocytopenia (ITP):a retrospective cohort study on longtime response predicting factors based on consensus criteria[J].Int J Surg,2014,12(12):1428-1433.
|
[11] |
Martin Arnau B,Turrado Rodriguez V,Tartaglia E,et al. Impact of preoperative platelet count on perioperative outcome after laparoscopic splenectomy for idiopathic thrombocytopenic purpura[J].Cir Esp,2016,94(7):399-403.
|
[12] |
侍阳,宋庆伟,于生才,等.腹腔镜脾切除术治疗难治性血小板减少性紫癜的临床应用[J].腹腔镜外科杂志,2014,19(5):356-358.
|
[13] |
曹卫刚,邱宝安.腹腔镜脾切除治疗特发性血小板减少性紫瘫九例体会[J].中华普外科手术学杂志(电子版),2014,8(2):168-170.
|
[14] |
Seong RH.Rapidly calcified all of multiple intracranial hemorrhages occurred in a patient with chronic idiopathic thrombocytopenic purpura[J].Interdisciplinary Neurosurg,2016,3(5):1024-0129.
|
[15] |
Tsai CH,Bussel JB,Imahiyerobo AA,et al.Platelet count control in immune thrombocytopenic purpura patient:optimum romiplostim dose profile[J].J Process Control,2016,45(45):1147-1151.
|